AML: Expert Guidance on Current Standards and New Directions in Patient Care

In this program, experts discuss how to identify patients using molecular and cytogenetic testing to optimally select recently approved agents to improve patient outcomes. Watch the on-demand Webcast, download the slides from a dynamic CCO symposium in Orlando, and access a downloadable summary resource.
Amir Fathi, MD
Jeffrey E. Lancet, MD
Farhad Ravandi, MD
Eunice S. Wang, MD

Downloadable Slidesets

Eunice S. Wang, MD, highlights the importance of biomarkers and MRD testing for optimal treatment of patients with AML.

Eunice S. Wang, MD Released: December 6, 2019

Amir Fathi, MD, provides expert insights and guidance on the best strategies to optimize treatment for patients with FLT3-mutant or IDH-mutant AML.

Amir Fathi, MD Released: December 6, 2019

Jeffrey E. Lancet, MD, provides expert insights and guidance on the best strategies to treat elderly and other patients with newly diagnosed AML.

Jeffrey E. Lancet, MD Released: December 6, 2019

Farhad Ravandi, MD, examines current and investigational AML treatment approaches using antibody-drug conjugates and other immunotherapies.

Farhad Ravandi, MD Released: December 9, 2019

Downloadable PDF

Download this PDF guide to best practices for the management of patients with acute myeloid leukemia.

Released: December 9, 2019
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Produced in collaboration with
NCCN Logo
Supported by educational grants from
Actinium Pharmaceuticals
Boston Biomedical, Inc.
Jazz Pharmaceuticals, Inc.
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue